Literature DB >> 23283356

Dexmedetomidine as a novel countermeasure for cocaine-induced central sympathoexcitation in cocaine-addicted humans.

Andrew C Kontak1, Ronald G Victor, Wanpen Vongpatanasin.   

Abstract

Cocaine-induced acute hypertension is mediated largely by increased central sympathetic nerve activity. We hypothesized that dexmedetomidine, a central sympatholytic, reverses cocaine-induced increases in sympathetic nerve activity, mean arterial pressure (MAP), and heart rate (HR) in cocaine-addicted subjects. First, we conducted a dose-finding study in 15 nontreatment-seeking cocaine-addicted subjects and 12 cocaine-naive healthy controls to find doses of intravenous dexmedetomidine that lower MAP and HR in the absence of acute-cocaine challenge. We then conducted a placebo-controlled treatment trial in 26 cocaine-addicted subjects to determine whether dexmedetomidine reverses MAP and HR increases after intranasal cocaine (3 mg/kg). Skin sympathetic nerve activity (measured in the second protocol) and skin vascular resistance (measured in both protocols) served as indices of cocaine-sensitive central sympathoexcitation. In doses up to 0.6 µg/kg IV, dexmedetomidine alone caused comparable dose-dependent decreases in blood pressure in cases and controls but a 1.0 µg/kg dose was required to lower HR. In cocaine-addicted subjects, low-dose dexmedetomidine (0.4 µg/kg; n=14) abolished cocaine-induced increases in skin sympathetic nerve activity (156 ± 26 versus -15 ± 22%, cocaine/placebo versus cocaine/dexmedetomidine; P<0.05), skin vascular resistance (+10 ± 2 versus -2 ± 3 U; P<0.05), and MAP (+6 ± 1 versus -5 ± 2 mm Hg; P<0.01) without affecting HR (+13 ± 2 versus +9 ± 2 bpm; P=ns). When dexmedetomidine was increased to 1 µg/kg (high dose; n=12) to reverse cocaine-induced increases in HR, MAP did not fall further and increased paradoxically in 4 of 12 subjects. Thus, in a low nonsedating dose, dexmedetomidine constitutes a putative new treatment for cocaine-induced acute hypertension but higher sedating doses can increase blood pressure unpredictably during acute-cocaine challenge and should be avoided.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23283356     DOI: 10.1161/HYPERTENSIONAHA.112.203554

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  10 in total

1.  Dexmedetomidine and regulation of splenic sympathetic nerve discharge.

Authors:  M J Kenney; B T Larsen; R M McMurphy; D Mason; R J Fels
Journal:  Auton Neurosci       Date:  2014-03-07       Impact factor: 3.145

2.  Dexmedetomidine and regulation of splenic sympathetic nerve discharge in aged F344 rats.

Authors:  R M McMurphy; R J Fels; M J Kenney
Journal:  Auton Neurosci       Date:  2015-03-14       Impact factor: 3.145

3.  Effects of anesthetic and sedative agents on sympathetic nerve activity.

Authors:  Xiao Liu; Perry L Rabin; Yuan Yuan; Awaneesh Kumar; Peter Vasallo; Johnson Wong; Gloria A Mitscher; Thomas H Everett; Peng-Sheng Chen
Journal:  Heart Rhythm       Date:  2019-06-25       Impact factor: 6.343

4.  Dexmedetomidine or midazolam in combination with propofol for sedation in endoscopic retrograde cholangiopancreatography: a randomized double blind prospective study.

Authors:  Senem Koruk; Irfan Koruk; Ayse Mizrak Arslan; Murat Bilgi; Rauf Gul; Semsettin Bozgeyik
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2020-05-10       Impact factor: 1.195

5.  Subcutaneous nerve stimulation reduces sympathetic nerve activity in ambulatory dogs with myocardial infarction.

Authors:  Yuan Yuan; Ye Zhao; Johnson Wong; Wei-Chung Tsai; Zhaolei Jiang; Ryan A Kabir; Seongwook Han; Changyu Shen; Michael C Fishbein; Lan S Chen; Zhenhui Chen; Thomas H Everett; Peng-Sheng Chen
Journal:  Heart Rhythm       Date:  2020-02-14       Impact factor: 6.343

6.  Cocaine-induced vasoconstriction in the human coronary microcirculation: new evidence from myocardial contrast echocardiography.

Authors:  Swaminatha V Gurudevan; Michael D Nelson; Florian Rader; Xiu Tang; Joshua Lewis; Jimmy Johannes; J Todd Belcik; Robert M Elashoff; Jonathan R Lindner; Ronald G Victor
Journal:  Circulation       Date:  2013-06-28       Impact factor: 29.690

7.  Dexmedetomidine alleviates postoperative cognitive dysfunction through circular RNA in aged rats.

Authors:  Cao Cao; Fumou Deng; Yanhui Hu
Journal:  3 Biotech       Date:  2020-03-24       Impact factor: 2.406

8.  Comparison of a loading dose of dexmedetomidine combined with propofol or sevoflurane for hemodynamic changes during anesthesia maintenance: a prospective, randomized, double-blind, controlled clinical trial.

Authors:  Yuan Han; Liu Han; Mengmeng Dong; Qingchun Sun; Ke Ding; Zhenfeng Zhang; Junli Cao; Yueying Zhang
Journal:  BMC Anesthesiol       Date:  2018-01-24       Impact factor: 2.217

9.  Is It Time for an Expanded Role of Dexmedetomidine in Contemporary Anesthesia Practice? - A Clinician's Perspective.

Authors:  Christian Bohringer; Hong Liu
Journal:  Transl Perioper Pain Med       Date:  2018-04-12

10.  Impact of intravenous dexmedetomidine on gastrointestinal function recovery after laparoscopic hysteromyomectomy: a randomized clinical trial.

Authors:  Yu Wu; Zenghua Cai; Lishuang Liu; Jinbao Wang; Yanli Li; Yuling Kang; Ni An
Journal:  Sci Rep       Date:  2022-08-27       Impact factor: 4.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.